Limits...
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy.

Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, Shin DM - Int J Nanomedicine (2008)

Bottom Line: Magnetic iron oxide (IO) nanoparticles with a long blood retention time, biodegradability and low toxicity have emerged as one of the primary nanomaterials for biomedical applications in vitro and in vivo.IO nanoparticles have a large surface area and can be engineered to provide a large number of functional groups for cross-linking to tumor-targeting ligands such as monoclonal antibodies, peptides, or small molecules for diagnostic imaging or delivery of therapeutic agents.IO nanoparticles possess unique paramagnetic properties, which generate significant susceptibility effects resulting in strong T2 and T*2 contrast, as well as T1 effects at very low concentrations for magnetic resonance imaging (MRI), which is widely used for clinical oncology imaging.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology/Hematology, Emory University School of Medicine, Atlanta, GA 30322, USA.

ABSTRACT
Magnetic iron oxide (IO) nanoparticles with a long blood retention time, biodegradability and low toxicity have emerged as one of the primary nanomaterials for biomedical applications in vitro and in vivo. IO nanoparticles have a large surface area and can be engineered to provide a large number of functional groups for cross-linking to tumor-targeting ligands such as monoclonal antibodies, peptides, or small molecules for diagnostic imaging or delivery of therapeutic agents. IO nanoparticles possess unique paramagnetic properties, which generate significant susceptibility effects resulting in strong T2 and T*2 contrast, as well as T1 effects at very low concentrations for magnetic resonance imaging (MRI), which is widely used for clinical oncology imaging. We review recent advances in the development of targeted IO nanoparticles for tumor imaging and therapy.

Show MeSH

Related in: MedlinePlus

T2 maps of the mice bearing underglycosylated mucin-1 antigen (uMUC-1)- positive (LS174T) and uMUC-1-negative (U87) tumors. Transverse (top) and coronal (bottom) images showed a significant (52%; P < 0.0001) decrease in signal intensity in uMUC-1-positive tumors 24 hrs after administration of the CLIO-EPPT probe. Copyright © 2004. Reproduced with permission from Moore A, Medarova Z, Potthast A, et al 2004. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res, 64:1821–7.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2626938&req=5

f3-ijn-3-311: T2 maps of the mice bearing underglycosylated mucin-1 antigen (uMUC-1)- positive (LS174T) and uMUC-1-negative (U87) tumors. Transverse (top) and coronal (bottom) images showed a significant (52%; P < 0.0001) decrease in signal intensity in uMUC-1-positive tumors 24 hrs after administration of the CLIO-EPPT probe. Copyright © 2004. Reproduced with permission from Moore A, Medarova Z, Potthast A, et al 2004. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res, 64:1821–7.

Mentions: Yang and colleagues (2007) developed a new multifunctional hybrid nanosystem by combining magnetic nano-crystals, anticancer drugs and biodegradable amphiphilic block copolymers. In this study, there were about 41.7 wt% (MnFe2O4) and 40.9wt% (Fe3O4) magnetic nanoparticles in the multifunctional magneto-polymeric nanohybrids (MMPNs), and the amount of DOXO in the HER-MMPNs and entrapment efficiency were 3.3 wt% and 71.4%, respectively. In addition, anti-HER antibody was conjugated to the MMPNs by utilizing the carboxyl group on the surface of the particles. As shown in Figure 3, the injected HER-MMPNs were delivered in a target-specific manner to overexpressed HER2/neu receptors on NIH3T6.7 cells in vivo and were taken up by a receptor-mediated endocytosis process. The HER-conjugated MMPNs showed significant synergistic effects on inhibition of tumor growth by DOXO. The antibody-conjugated nanoparticles also demonstrated ultrasensitive targeted detection by MRI in both in vitro and in vivo models (Yang et al 2007).


Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy.

Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, Shin DM - Int J Nanomedicine (2008)

T2 maps of the mice bearing underglycosylated mucin-1 antigen (uMUC-1)- positive (LS174T) and uMUC-1-negative (U87) tumors. Transverse (top) and coronal (bottom) images showed a significant (52%; P < 0.0001) decrease in signal intensity in uMUC-1-positive tumors 24 hrs after administration of the CLIO-EPPT probe. Copyright © 2004. Reproduced with permission from Moore A, Medarova Z, Potthast A, et al 2004. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res, 64:1821–7.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2626938&req=5

f3-ijn-3-311: T2 maps of the mice bearing underglycosylated mucin-1 antigen (uMUC-1)- positive (LS174T) and uMUC-1-negative (U87) tumors. Transverse (top) and coronal (bottom) images showed a significant (52%; P < 0.0001) decrease in signal intensity in uMUC-1-positive tumors 24 hrs after administration of the CLIO-EPPT probe. Copyright © 2004. Reproduced with permission from Moore A, Medarova Z, Potthast A, et al 2004. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res, 64:1821–7.
Mentions: Yang and colleagues (2007) developed a new multifunctional hybrid nanosystem by combining magnetic nano-crystals, anticancer drugs and biodegradable amphiphilic block copolymers. In this study, there were about 41.7 wt% (MnFe2O4) and 40.9wt% (Fe3O4) magnetic nanoparticles in the multifunctional magneto-polymeric nanohybrids (MMPNs), and the amount of DOXO in the HER-MMPNs and entrapment efficiency were 3.3 wt% and 71.4%, respectively. In addition, anti-HER antibody was conjugated to the MMPNs by utilizing the carboxyl group on the surface of the particles. As shown in Figure 3, the injected HER-MMPNs were delivered in a target-specific manner to overexpressed HER2/neu receptors on NIH3T6.7 cells in vivo and were taken up by a receptor-mediated endocytosis process. The HER-conjugated MMPNs showed significant synergistic effects on inhibition of tumor growth by DOXO. The antibody-conjugated nanoparticles also demonstrated ultrasensitive targeted detection by MRI in both in vitro and in vivo models (Yang et al 2007).

Bottom Line: Magnetic iron oxide (IO) nanoparticles with a long blood retention time, biodegradability and low toxicity have emerged as one of the primary nanomaterials for biomedical applications in vitro and in vivo.IO nanoparticles have a large surface area and can be engineered to provide a large number of functional groups for cross-linking to tumor-targeting ligands such as monoclonal antibodies, peptides, or small molecules for diagnostic imaging or delivery of therapeutic agents.IO nanoparticles possess unique paramagnetic properties, which generate significant susceptibility effects resulting in strong T2 and T*2 contrast, as well as T1 effects at very low concentrations for magnetic resonance imaging (MRI), which is widely used for clinical oncology imaging.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology/Hematology, Emory University School of Medicine, Atlanta, GA 30322, USA.

ABSTRACT
Magnetic iron oxide (IO) nanoparticles with a long blood retention time, biodegradability and low toxicity have emerged as one of the primary nanomaterials for biomedical applications in vitro and in vivo. IO nanoparticles have a large surface area and can be engineered to provide a large number of functional groups for cross-linking to tumor-targeting ligands such as monoclonal antibodies, peptides, or small molecules for diagnostic imaging or delivery of therapeutic agents. IO nanoparticles possess unique paramagnetic properties, which generate significant susceptibility effects resulting in strong T2 and T*2 contrast, as well as T1 effects at very low concentrations for magnetic resonance imaging (MRI), which is widely used for clinical oncology imaging. We review recent advances in the development of targeted IO nanoparticles for tumor imaging and therapy.

Show MeSH
Related in: MedlinePlus